Another thing to bear in mind is that Kineta immuno-oncology...

Another thing to bear in mind is that Kineta immuno-oncology therapies are at the discovery phase, so not even in pre-clinical trials yet.

I think so many asx investors think that imu will only get a deal after phase 2 results, but these game changing therapies can get deals very early on.

imu now have strong evidence of efficacy, but also an incredible safety profile. That safety is believed to be because they are using B cells, so the patient produces their own (safe) antibodies.

All T cells therapies can be reversed engineered and turned into B cell therapies by imu. So all those nasty side effects that the big selling new T cell therapies have can probably be wiped out in a flash.

As I said before, while the asx didn't like imu's ann, we took a big step closer to a deal/takeover yesterday imho.

cheers

https://www.kinetabio.com/pipeline/